Last reviewed · How we verify
Tredaptive
At a glance
| Generic name | Tredaptive |
|---|---|
| Also known as | Tedaptive |
| Sponsor | Sheba Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers (PHASE4)
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (PHASE4)
- Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome (PHASE4)
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (PHASE3)
- The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients (PHASE4)
- A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED) (PHASE1)
- Lipid Management in Clinical Practice (MK-0524A-115)
- Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tredaptive CI brief — competitive landscape report
- Tredaptive updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI